RT Journal Article
SR Electronic
T1 Using Population Based Kalman Estimator to Model COVID-19 Epidemic in France: Estimating the Effects of Non-Pharmaceutical Interventions on the Dynamics of Epidemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.09.21260259
DO 10.1101/2021.07.09.21260259
A1 Annabelle Collin
A1 Boris P. Hejblum
A1 Carole Vignals
A1 Laurent Lehot
A1 Rodolphe Thiébaut
A1 Philippe Moireau
A1 MéLanie Prague
YR 2021
UL http://medrxiv.org/content/early/2021/07/16/2021.07.09.21260259.abstract
AB In response to the ongoing COVID-19 pandemic caused by SARS-CoV-2, governments are taking a wide range of non-pharmaceutical interventions (NPI). These measures include interventions as stringent as strict lockdown but also school closure, bar and restaurant closure, curfews and barrier gestures i.e. social distancing. Disentangling the effectiveness of each NPI is crucial to inform response to future outbreaks. To this end, we first develop a multi-level estimation of the French COVID-19 epidemic over a period of one year. We rely on a global extended Susceptible-Infectious-Recovered (SIR) mechanistic model of the infection including a dynamical (over time) transmission rate containing a Wiener process accounting for modeling error. Random effects are integrated following an innovative population approach based on a Kalman-type filter where the log-likelihood functional couples data across French regions. We then fit the estimated time-varying transmission rate using a regression model depending on NPI, while accounting for vaccination coverage, apparition of variants of concern (VoC) and seasonal weather conditions. We show that all NPI considered have an independent significant effect on the transmission rate. We additionally demonstrate a strong effect from weather conditions which decrease transmission during the summer period, and also estimate increased transmissibility of VoCs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported in part by Inria Mission COVID19, project GESTEPID.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:n/aAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used are available from the data.gouv.fr website of the French government. https://www.data.gouv.fr/fr/